Maissa Mhibik

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 4

Top Topics

Magnetic Resonance

Tyrosine Kinase

Chronic Lymphocytic Leukemia

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Anfal Alsadhan, Jonathan Chen, Erika M Gaglione, Chingiz Underbayev, Pamela L Tuma, Xin Tian, Lita A Freeman, Sivasubramanian Baskar, Pia Nierman, Susan Soto, Andy Itsara, Inhye E Ahn, Clare Sun, Elena Bibikova, Tanja Nicole Hartmann, Maissa Mhibik, Adrian Wiestner
CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Anfal Alsadhan, Jonathan Chen, Erika M Gaglione, Chingiz Underbayev, Pamela L Tuma, Xin Tian, Lita A Freeman, Sivasubramanian Baskar, Pia Nierman, Susan Soto, Andy Itsara, Inhye E Ahn, Clare Sun, Elena Bibikova, Tanja Nicole Hartmann, Maissa Mhibik, Adrian Wiestner
CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Matthew G Cyr, Maissa Mhibik, Junpeng Qi, Haiyong Peng, Jing Chang, Erika M Gaglione, David Eik, John Herrick, Thomas Venables, Scott J Novick, Valentine V Courouble, Patrick R Griffin, Adrian Wiestner, Christoph Rader
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia. Journal for immunotherapy of cancer 10 (11) (2022)
Maissa Mhibik, Erika M Gaglione, David Eik, Ellen K Kendall, Amy Blackburn, Keyvan Keyvanfar, Maria Joao Baptista, Inhye E Ahn, Clare Sun, Junpeng Qi, Christoph Rader, Adrian Wiestner
BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL. Blood 138 (19) (2021)